최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
DataON 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Edison 바로가기다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
Kafe 바로가기국가/구분 | United States(US) Patent 등록 |
---|---|
국제특허분류(IPC7판) |
|
출원번호 | US-0131591 (2009-12-02) |
등록번호 | US-9394333 (2016-07-19) |
국제출원번호 | PCT/IB2009/007923 (2009-12-02) |
§371/§102 date | 20110819 (20110819) |
국제공개번호 | WO2010/064146 (2010-06-10) |
발명자 / 주소 |
|
출원인 / 주소 |
|
대리인 / 주소 |
|
인용정보 | 피인용 횟수 : 13 인용 특허 : 256 |
Described herein are methods of syntheses of phosphorous atom-modified nucleic acids comprising chiral X-phosphonate moieties. The methods described herein provide backbone-modified nucleic acids in high diasteteomeric purity via an asymmetric reaction of an achiral molecule comprising a chemically
Described herein are methods of syntheses of phosphorous atom-modified nucleic acids comprising chiral X-phosphonate moieties. The methods described herein provide backbone-modified nucleic acids in high diasteteomeric purity via an asymmetric reaction of an achiral molecule comprising a chemically stable H-phophonate moiety with a nucleoside/nucleotide.
1. A method for a synthesis of a nucleic acid comprising a chiral X-phosphonate moiety comprising: reacting a molecule comprising an achiral H-phosphonate moiety, a chiral reagent, and a nucleoside comprising a 5′-OH moiety to form a condensed intermediate; andconverting the condensed intermediate t
1. A method for a synthesis of a nucleic acid comprising a chiral X-phosphonate moiety comprising: reacting a molecule comprising an achiral H-phosphonate moiety, a chiral reagent, and a nucleoside comprising a 5′-OH moiety to form a condensed intermediate; andconverting the condensed intermediate to the nucleic acid comprising a chiral X-phosphonate moiety; wherein:each instance of X is independently an optionally substituted group selected from alkyl, alkoxy, aryl, alkylthio, acyl, —NRfRf, alkenyloxy, alkynyloxy, alkenylthio, alkynylthio, —S−Z+, Se−Z+, and —BH3−Z+;each instance of Rf is independently hydrogen, alkyl, alkenyl, alkynyl, or aryl; andZ+ is ammonium ion, alkylammonium ion, heteroaromatic iminium ion, or heterocyclic iminium ion, any of which is primary, secondary, tertiary or quaternary, or Z+ is a monovalent metal ion. 2. The method of claim 1 wherein the step of reacting the molecule comprising an achiral H-phosphonate moiety and the nucleoside comprising a 5′-OH moiety to form a condensed intermediate is a one-pot reaction. 3. The method of claim 1 wherein the nucleic acid comprising a chiral X-phosphonate moiety is a compound of Formula 1: wherein R1 is —OH, —SH, —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —P(O)(Re)2, —HP(O)(Re), —ORa or —SRc;Y1 is O, NRd, S, or Se;Ra is a blocking moiety;Rc is a blocking group;each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);each instance of Re is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—, or a cation which is Na+1, Li+1, or K+1;Y2 is O, NRd, or S, wherein Rd is hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, or carbamate;each instance of R2 is independently hydrogen, —OH, —SH, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, wherein Rb is a blocking moiety;each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase;each instance of X is independently alkyl, alkoxy, aryl, alkylthio, acyl, —NRfRf, alkenyloxy, alkynyloxy, alkenylthio, alkynylthio, —S−Z+, —Se−Z+, or —BH3−Z+;each instance of Rf is independently hydrogen, alkyl, alkenyl, alkynyl, or aryl;Z+ is ammonium ion, alkylammonium ion, heteroaromatic iminium ion, or heterocyclic iminium ion, any of which is primary, secondary, tertiary or quaternary, or Z+ is a monovalent metal ion;R3 is hydrogen, a blocking group, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid; andn is an integer of 1 to about 200. 4. The method of claim 3 wherein each X-phosphonate moiety of the compound of Formula 1 is more than 98% diastereomerically pure as determined by 31P NMR spectroscopy or reverse-phase HPLC. 5. The method of claim 3 wherein each X-phosphonate moiety has a Sp configuration. 6. The method of claim 1 wherein the molecule comprising an achiral H-phosphonate moiety is a compound of Formula 2: wherein R1 is —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, heteroaryl-Y1—, —P(O)(Re)2, —HP(O)(Re), —ORa, or —SRc;Y1 is O, NRd, S, or Se;Ra is a blocking moiety;Rc is a blocking group;each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);each instance of Re is independently alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—;Y2 is O, NRd, or S, wherein Rd is hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, or carbamate;R2 is hydrogen, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, wherein Rb is a blocking moiety; andBa is a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase; andZ+ is ammonium ion, alkylammonium ion, heteroaromatic iminium ion, or heterocyclic iminium ion, any of which is primary, secondary, tertiary or quaternary, or a monovalent metal ion. 7. The method of claim 1, wherein reacting a molecule comprising an achiral H-phosphonate moiety and a nucleoside comprising a 5′-OH moiety to form a condensed intermediate is performed without isolating any intermediates. 8. The method of claim 7 wherein the chiral reagent is a compound of Formula 3: wherein:W1 and W2 are independently —NG5-, —O—, or —S—;G1, G2, G3, G4, and G5 are independently hydrogen, alkyl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetaryl, or aryl, or two of G1, G2, G3, G4, and G5 are G6 taken together to form a saturated, partially unsaturated or unsaturated carbocyclic or heteroatom-containing ring of up to about 20 ring atoms which is monocyclic or polycyclic, fused or unfused, and wherein no more than four of G1, G2, G3, G4, and G5 are G6. 9. The method of claim 3 wherein the nucleoside comprising a 5′-OH moiety is a compound of Formula 4: wherein each instance of R2 is independently hydrogen, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, wherein Rb is a blocking moiety;Y1 is O, NRd, S, or Se;Rc is a blocking group;each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);each instance of Re is independently alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—;Y2 is O, NRd, or S, wherein Rd is hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, or carbamate;each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase;m is an integer of 0 to n−1;n is an integer of 1 to about 200;OA is connected to a trityl moiety, a silyl moiety, an acetyl moiety, an acyl moiety, an aryl acyl moiety, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid;J is O and D is H; or J is S, Se, or BH3, and D is a moiety of Formula A: wherein W1 and W2 are independently NG5, O, or S;A is hydrogen, acyl, aryl, alkyl, aralkyl, or silyl moiety; andwherein G1, G2, G3, G4, and G5 are independently hydrogen, alkyl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heteroaryl, or aryl, or two of G1, G2, G3, G4, and G5 are G6 which are taken together to form a saturated, partially unsaturated or unsaturated carbocyclic or heteroatom-containing ring of up to about 20 ring atoms which is monocyclic or polycyclic, fused or unfused and wherein no more than four of G1, G2, G3, G4, and G5 are G6. 10. The method of claim 7 further comprising providing a condensing reagent CR whereby the molecule comprising an achiral H-phosphonate moiety is activated to react with the chiral reagent to form a chiral intermediate. 11. The method of claim 10 wherein the condensing reagent CR is Ar3PL2, (ArO)3PL2, whereinZ1, Z2, Z3, Z4, Z5, Z6, Z7, Z8, Z9 and Z10 are independently alkyl, aminoalkyl, cycloalkyl, heterocyclic, cycloalkylalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxy, aryloxy, or heteroaryloxy, or wherein any of Z2 and Z3, Z5 and Z6, Z7 and Z8, Z8 and Z9, Z9 and Z7, or Z7 and Z8 and Z9 are taken together to form a 3 to 20 membered alicyclic or heterocyclic ring;Q− is a counter anion;L is a leaving group;w is an integer of 0 to 3; andAr is aryl, heteroaryl, and/or one of Ar group is attached to a polymer support. 12. The method of claim 10 wherein the condensing reagent is bis(trichloromethyl)carbonate (BTC), (Ph0)3PCl2, Ph3PCl2, N,N′-bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BopCl), 1,3-dimethyl-2-(3-nitro-1,2,4-triazol-1-yl)-2-pyrrolidin-1-yl-1,3,2-diazaphospholidinium hexafluorophosphate (MNTP), or 3-nitro-1,2,4-triazol-1-yl-tris(pyrrolidin-1-yl)phosphonium hexafluorophosphate (PyNTP) 13. The method of claim 10 further comprising providing an activating reagent AR. 14. The method of claim 13 wherein the activating reagent AR is wherein Z11, Z12, Z13, Z14, Z15, Z16, Z17, Z18, Z19, Z20, and Z21 are independently hydrogen, alkyl, aminoalkyl, cycloalkyl, heterocyclic, cycloalkylalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxy, aryloxy, or heteroaryloxy, or wherein any of Z11 and Z12, Z11 and Z13, Z11 and Z14, Z12 and Z13, Z12 and Z14, Z13 and Z14, Z15 and Z16, Z15 and Z17, Z16 and Z17, Z18 and Z19, or Z20 and Z21 are taken together to form a 3 to 20 membered alicyclic or heterocyclic ring, or to form 5 or 20 membered aromatic ring; and Q— is a counter ion. 15. The method of claim 13 wherein the activating reagent AR is imidazole, 4,5-dicyanoimidazole (DCI), 4,5-dichloroimidazole, 1-phenylimidazolium triflate (PhIMT), benzimidazolium triflate (BIT), benztriazole, 3-nitro-1,2,4-triazole (NT), tetrazole, 5-ethylthiotetrazole, 5-(4-nitrophenyl)tetrazole, N-cyanomethylpyrrolidinium triflate (CMPT), N-cyanomethylpiperidinium triflate, N-cyanomethyldimethylammonium triflate. 16. The method of claim 13 wherein the activating reagent AR is N-cyanomethylpyrrolidinium triflate (CMPT). 17. The method of claim 1 wherein the reaction is performed in an aprotic organic solvent. 18. The method of claim 17 wherein the solvent is acetonitrile, pyridine, tetrahydrofuran, or dichloromethane. 19. The method of claim 17 wherein when the aprotic organic solvent is not basic, a base is present in the reacting step. 20. The method of claim 19 wherein the base is pyridine, quinoline, N,N-dimethylaniline or N-cyanomethylpyrrolidine. 21. The method of claim 19 wherein the base is wherein Z22 and Z23 are independently alkyl, aminoalkyl, cycloalkyl, heterocyclic, cycloalkylalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxy, aryloxy, or heteroaryloxy, or wherein any of Z22 and Z23 are taken together to form a 3 to 10 membered alicyclic or heterocyclic ring. 22. The method of claim 17 wherein the aprotic organic solvent is anhydrous. 23. The method of claim 22 wherein the anhydrous aprotic organic solvent is freshly distilled. 24. The method of claim 23 wherein the freshly distilled anhydrous aprotic organic solvent is pyridine or acetonitrile. 25. The method of claim 9 wherein the step of converting the condensed intermediate to a compound of Formula 1 comprises: capping the condensed intermediate and modifying the capped condensed intermediate to produce a compound of Formula 5: wherein R1 is —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —P(O)(Re)2, —HP(O)(Re), —ORa, or —SRc;Y1 is O, NRd, S, or Se;Ra is a blocking moiety;Rc is a blocking group;each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);each instance of Re is independently alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—;Y2 is O, NRd, or S, wherein Rd is hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, or carbamate;each instance of R2 is independently hydrogen, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, wherein Rb is a blocking moiety;each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil, or modified nucleobase;each instance of J is S, Se, or BH3;v is an integer of 2 to n−1;OA is connected to a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid;A is an acyl, aryl, alkyl, aralkyl, or silyl moiety; andG1, G2, G3, G4, and G5 are independently hydrogen, alkyl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heteroaryl, or aryl, or two of G1, G2, G3, G4, and G5 are G6 which are taken together to form a saturated, partially unsaturated or unsaturated carbocyclic or heteroatom-containing ring of up to about 20 ring atoms which is monocyclic or polycyclic, fused or unfused and wherein no more than four of G1, G2, G3, G4, and G5 are G6. 26. The method of claim 25 further comprising the steps of: (a) deblocking R1 of the compound of Formula 5 to produce a compound of Formula 4 wherein m is at least 1, J is S, Se, or BH3 and D is a moiety of Formula A; (b) reacting the compound of Formula 4 wherein the step of converting the condensed intermediate comprises capping the condensed intermediate and modifying the capped condensed intermediate to produce a compound of Formula 5 wherein v is greater than 2 and less than about 200; and (c) optionally repeating steps (a) and (b) to form a compound of Formula 5 wherein v is greater than 3 and less than about 200. 27. The method of claim 25 further comprising the step of converting the compound of Formula 5 to the compound of Formula 1 wherein each Ba moiety is unblocked; R1 is —OH, —SH, —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —P(O)(Re)2, —HP(O)(Re), —ORa, or —SRc; Y1 is O, NRd, S, or Se;Ra is a blocking moiety;Rc is a blocking group;each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);each instance of Re is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—, or a cation which is Na+1, Li+1, or K+1;Y2 is O, NRd, or S, wherein Rd is hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, or carbamate;each instance of R2 is independently hydrogen, —OH, —SH, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—;R3 is H;each instance of X is independently —S−Z+, —Se−Z+, or —BH3−Z+; andZ+ is ammonium ion, alkylammonium ion, heteroaromatic iminium ion, or heterocyclic iminium ion, any of which is primary, secondary, tertiary or quaternary, or Z+ is a monovalent metal ion. 28. The method of claim 3 wherein the step of converting the condensed intermediate to a compound of Formula 1 comprises acidifying the condensed intermediate to produce a compound of Formula 4: wherein each instance of R2 is independently hydrogen, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —ORb, or —SRc, wherein Rb is a blocking moiety;Y1 is O, NRd, S, or Se;Rc is a blocking group;each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);each instance of Re is independently alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—;Y2 is O, NRd, or S, wherein Rd is hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, or carbamate;each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or modified nucleobase;m is an integer of 1 to n−1;n is an integer of 2 to about 200;OA is connected to a trityl moiety, a silyl moiety, an acetyl moiety, an acyl moiety, an aryl acyl moiety, a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid;J is 0; andD is H. 29. The method of claim 28 wherein the condensed intermediate comprises a moiety of Formula A′: wherein A is hydrogen; andwherein G1 and G2 are independently alkyl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, or aryl and G3, G4, and G5 are independently hydrogen, alkyl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heteroaryl, or aryl, or two of G1, G2, G3, G4, and G5 are G6 which are taken together to form a saturated, partially unsaturated or unsaturated carbocyclic or heteroatom-containing ring of up to about 20 ring atoms which is monocyclic or polycyclic, fused or unfused and wherein no more than four of G1, G2, G3, G4, and G5 are G6. 30. The method of claim 28 further comprising: (a) reacting the compound of Formula 4 wherein m is at least one, J is O, and D is H, an achiral H-phosphonate moiety and a chiral reagent to form a condensed intermediate without isolating any intermediates, wherein: the chiral reagent is a compound of Formula 3: wherein:W1 and W2 are independently —NG5-, —O—, or —S—;G1, G2, G3, G4, and G5 are independently hydrogen, alkyl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, hetaryl, or aryl, or two of G1, G2, G3, G4, and G5 are G6 taken together to form a saturated, partially unsaturated or unsaturated carbocyclic or heteroatom-containing ring of up to about 20 ring atoms which is monocyclic or polycyclic, fused or unfused, and wherein no more than four of G1, G2, G3, G4, and G5 are G6; and wherein the step of converting the condensed intermediate to a compound of Formula 1 comprises acidifying the condensed intermediate to produce a compound of Formula 4 wherein m is at least 2 and less than about 200, J is O, and D is H, and (b) optionally repeating step (a) to produce a compound of Formula 4 wherein m is greater than 2 and less than about 200. 31. The method of claim 28 wherein the acidifying comprises adding an amount of a Brønsted or Lewis acid effective to convert the condensed intermediate into the compound of Formula 4 without removing purine or pyrimidine moieties from the condensed intermediate. 32. The method of claim 31 wherein the acidifying comprises adding 1% trilfuoroacetic acid in an organic solvent, 3% dichloroacetic acid in an organic solvent, or 3% trichloroacetic acid in an organic solvent. 33. The method of claim 28 wherein the acidifying further comprises adding a cation scavenger. 34. The method of claim 28 wherein the step of converting the condensed intermediate to a compound of Formula 1 further comprises deblocking Ri prior to the step of acidifying the condensed intermediate. 35. The method of claim 28 further comprising the step of modifying the compound of Formula 4 to introduce an X moiety thereby producing a compound of Formula 1 wherein R3 is a blocking group or a linking moiety connected to a solid support. 36. The method of claim 35 further comprising treating the compound of Formula 4 to produce a compound of Formula 1, wherein Rl is —OH, —SH, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—, —P(O)(Re)2, —HP(O)(Re), —ORa or —SRc; Y1 is O, NRd, S, or Se;Ra is a blocking moiety;Rc is a blocking group;each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);each instance of Re is independently hydrogen, alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—, or a cation which is Na+1, Li+1, or K+1;Y2 is O, NRd, or S, wherein Re is hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, or carbamate;each instance of R2 is independently hydrogen, —OH, —SH, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y1—;each Ba moiety is unblocked;R3 is H;each instance of X is independently alkyl, alkoxy, aryl, alkylthio, acyl, —NRfRf, alkenyloxy, alkynyloxy, alkenylthio, alkynylthio, —S−Z+, —Se−Z+, or —BH3−Z+;each instance of Rf is independently hydrogen, alkyl, alkenyl, alkynyl, or aryl;Z+ is ammonium ion, alkylammonium ion, heteroaromatic iminium ion, or heterocyclic iminium ion, any of which is primary, secondary, tertiary or quaternary, or Z+ is a monovalent metal ion; andn is greater than 1 and less than about 200. 37. The method of claim 25 wherein the modifying step is performed using a boronating agent, a sulfur electrophile, or a selenium electrophile. 38. The method of claim 37 wherein the sulfur electrophile is a compound having one of the following formulae: Z24—S—S—Z25, or Z24—S—X—Z25, S8 (Formula B),wherein Z24 and Z25 are independently alkyl, aminoalkyl, cycloalkyl, heterocyclic, cycloalkylalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxy, aryloxy, heteroaryloxy, acyl, amide, imide, or thiocarbonyl, or Z24 and Z25 are taken together to form a 3 to 8 membered alicyclic or heterocyclic ring, which may be substituted or unsubstituted;X is SO2, O, or NRf; and Rf is hydrogen, alkyl, alkenyl, alkynyl, or aryl. 39. The method of claim 38 wherein the sulfur electrophile is a compound of Formula B, C, D, E, or F: 40. The method of claim 37 wherein the selenium electrophile is a compound having one of the following formulae: Z26—Se—Se—Z27, or Z26—Se—X—Z27, Se (Formula G),wherein Z26 and Z27 are independently alkyl, aminoalkyl, cycloalkyl, heterocyclic, cycloalkylalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxy, aryloxy, heteroaryloxy, acyl, amide, imide, or thiocarbonyl, or Z26 and Z27 are taken together to form a 3 to 8 membered alicyclic or heterocyclic ring, which may be substituted or unsubstituted;X is SO2, O, S, or NRf; and Rf is hydrogen, alkyl, alkenyl, alkynyl, or aryl. 41. The method of claim 40 wherein the selenium electrophile is a compound of Formula G, H, I, J, K, or L 42. The method of claim 37 wherein the boronating agent is borane-N,N-diisopropylethylamine (BH3.DIPEA), borane-pyridine (BH3*Py), borane-2-chloropyridine (BH3.CPy), borane-aniline (BH3.An), borane-tetrahydrofurane (BH3.THF), or borane-dimethyl sulfide (BH3.Me2S). 43. The method of claim 35 wherein the modifying step is performed using a silylating reagent followed by a sulfur electrophile, a selenium electrophile, a boronating agent, an alkylating agent, an aldehyde, or an acylating agent. 44. The method of claim 43 wherein the silylating reagent is chlorotrimethylsilane (TMS-Cl), triisopropylsilylchloride (TIPS-Cl), t-butyldimethylsilylchloride (TBDMS-Cl), t-butyldiphenylsilylchloride (TBDPS-Cl), 1,1,1,3,3,3-hexamethyldisilazane (HIVIDS), N-trimethyl silyldimethylamine (TMSDMA), N-trimethylsilyldiethylamine (TMSDEA), N-trimethylsilylacetamide (TMSA), N,O-bis(trimethylsilyl)acetamide (BSA), or N,O-bis(trimethylsilyl)trifluoroacetamide (BSTFA). 45. The method of claim 43 wherein the sulfur electrophile is a compound having one of the following formulae: Z24—S—S—Z25, or Z24—S—X—Z25, S8 (Formula B),wherein Z24 and Z25 are independently alkyl, aminoalkyl, cycloalkyl, heterocyclic, cycloalkylalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxy, aryloxy, heteroaryloxy, acyl, amide, imide, or thiocarbonyl, or Z24 and Z25 are taken together to form a 3 to 8 membered alicyclic or heterocyclic ring, which may be substituted or unsubstituted;X is SO2, O, or NRf; and Rf is hydrogen, alkyl, alkenyl, alkynyl, or aryl. 46. The method of claim 45 wherein the sulfur electrophile is a compound of Formula B, C, D, E, or F: 47. The method of claim 43 wherein the selenium electrophile is a compound having one of the following formulae: Z26—Se—Se—Z27, or Z26—Se—X—Z27, Se (Formula G),wherein Z26 and Z27 are independently alkyl, aminoalkyl, cycloalkyl, heterocyclic, cycloalkylalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxy, aryloxy, heteroaryloxy, acyl, amide, imide, or thiocarbonyl, or Z26 and Z27 are taken together to form a 3 to 8 membered alicyclic or heterocyclic ring, which may be substituted or unsubstituted;X is SO2, O, S, or NRf; and Rf is hydrogen, alkyl, alkenyl, alkynyl, or aryl. 48. The method of claim 40 wherein the selenium electrophile is a compound of Formula G, H, I, J, K, or L 49. The method of claim 43 wherein the boronating agent is borane-N,N-diisopropylethylamine (BH3.DIPEA), borane-pyridine (BH3*Py), borane-2-chloropyridine (BH3.CPy), borane-aniline (BH3.An), borane-tetrahydrofurane (BH3.THF), or borane-dimethyl sulfide (BH3.Me2S). 50. The method of claim 43 wherein the alkylating agent is an alkyl halide, alkenyl halide, alkynyl halide, alkyl sulfonate, alkenyl sulfonate, or alkynyl sulfonate. 51. The method of claim 43 wherein the aldehyde is (para)-formaldehyde, alkyl aldehyde, alkenyl aldehyde, alkynyl aldehyde, or aryl aldehyde. 52. The method of claim 43 wherein the acylating agent is a compound of Formula M or N: wherein G7 is alkyl, cycloalkyl, heterocyclic, cycloalkylalkyl, heterocycloalkyl, aryl, heteroaryl, alkyloxy, aryloxy, or heteroaryloxy; andM is F, Cl, Br, I, 3-nitro-1,2,4-triazole, imidazole, alkyltriazole, tetrazole, pentafluorobenzene, or 1-hydroxybenzotriazole. 53. The method of claim 35 wherein the modifying step is performed by reacting with a halogenating reagent followed by reacting with a nucleophile. 54. The method of claim 53 wherein the halogenating reagent is CCl4, CBr4, Cl2, Br2, I2, sulfuryl chloride (SO2Cl2), phosgene, bis(trichloromethyl)carbonate (BTC), sulfur monochloride, sulfur dichloride, chloramine, CuCl2, N-chlorosuccinimide (NCS), CI4, N-bromosuccinimide (NBS), or N-iodosuccinimide (NIS). 55. The method of claim 53 wherein the nucleophile is NRfRfH, RfOH, or RfSH, wherein Rf is hydrogen, alkyl, alkenyl, alkynyl, or aryl, and at least one of Rf of NRfRfH is not hydrogen. 56. The method of claim 8 wherein the chiral reagent is the compound of Formula 3 wherein W1 is NG5 and W2 is O. 57. The method of claim 8 wherein the chiral reagent is Formula O, Formula P, Formula Q or Formula R: 58. The method of claim 3, wherein Ra is substituted or unsubstituted trityl or substituted silyl. 59. The method of claim 3, wherein Rb is substituted or unsubstituted trityl, substituted silyl, acetyl, acyl, or substituted methyl ether. 60. The method of claim 3 wherein R3 is a blocking group which is substituted trityl, acyl, substituted silyl, or substituted benzyl. 61. The method of claim 3 wherein R3 is a linking moiety connected to a solid support. 62. The method of claim 3, wherein the blocking group of the Ba moiety is a benzyl, acyl, formyl, dialkylformamidinyl, isobutyryl, phenoxyacetyl, or trityl moiety, any of which may be unsubstituted or substituted. 63. The method of claim 3, wherein R1 is —N3, —NRdRd, alkynyloxy, or —OH. 64. The method of claim 35, wherein Ri is —N3, —NRdRd, alkynyloxy, or —OH. 65. The method of claim 3, wherein R2 is —NRdRd, alkyl, alkenyl, alkynyl, heteroaryl-Y1 and is substituted with fluorescent or biomolecule binding moieties. 66. The method of claim 65 wherein the substituent on R2 is a fluorescent moiety. 67. The method of claim 65 wherein the substituent on R2 is a biotin or avidin. 68. The method of claim 3, wherein R2 is —OH, —N3, hydrogen, halogen, alkoxy, or alkynyloxy. 69. The method of claim 35, wherein R2 is —OH, —N3, hydrogen, halogen, alkoxy, or alkynyloxy. 70. The method of claim 35 wherein Ba is 5-bromouracil, 5-iodouracil, or 2,6-diaminopurine. 71. The method of claim 3, wherein Ba is modified by substitution with a fluorescent or biomolecule binding moiety. 72. The method of claim 71 wherein the substituent on Ba is a fluorescent moiety. 73. The method of claim 71 wherein the substituent on Ba is biotin or avidin. 74. The method of claim 3, wherein Z is pyridinium ion, triethylammonium ion, N,N-diisopropylethylammonium ion, 1,8-diazabicyclo[5.4.0]undec-7-enium ion, sodium ion, or potassium ion. 75. The method of claim 3 wherein X is alkyl, alkoxy, —NRfRf, —S—Z+, or —BH3—Z+. 76. The method of claim 39 wherein the sulfur electrophile is Formula F, Formula E or Formula B. 77. The method of claim 46 wherein the sulfur electrophile is Formula F, Formula E or Formula B. 78. The method of claim 41 wherein the selenium electrophile is Formula G or Formula J. 79. The method of claim 48 wherein the selenium electrophile is Formula G or Formula J. 80. The method of claim 42 wherein the boronating agent is borane-N,N-diisopropylethylamine (BH3.DIPEA), borane-2-chloropyridine (BH3.CPy), borane-tetrahydrofurane (BH3.THF), or borane-dimethyl sulfide (BH3.Me2S). 81. The method of claim 54 wherein the halogenating agent is CCl4, CBr4, Cl2, sulfuryl chloride (SO2Cl2), or N-chlorosuccinimide (NCS). 82. The method of claim 12 wherein the condensing reagent is bis(trichloromethyl)carbonate (BTC), (PhO)3PCl2, Ph3PCl2, or N,N-bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BopCl). 83. The method of claim 3 wherein the step of converting the condensed intermediate to a compound of Formula 1 comprises: modifying the condensed intermediate to produce a compound of Formula 5: wherein R1 is —NRdRd, —N3, halogen, hydrogen, alkyl, alkenyl, alkynyl, heteroaryl-Y1—, —P(O)(Re)2, —HP(O)(Re), —ORa, or —SRc;Y1 is O, NRd, S, or Se;Ra is a blocking moiety;Rc is a blocking group;each instance of Rd is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, carbamate, —P(O)(Re)2, or —HP(O)(Re);each instance of Re is independently alkyl, aryl, alkenyl, alkynyl, alkyl-Y2—, alkenyl-Y2—, alkynyl-Y2—, aryl-Y2—, or heteroaryl-Y2—;Y2 is O, NRd, or S, wherein Rd is hydrogen, alkyl, alkenyl, alkynyl, aryl, acyl, substituted silyl, or carbamate;each instance of R2 is independently hydrogen, —NRdRd, —N3, halogen, alkyl, alkenyl, alkynyl, alkyl-Y1—, alkenyl-Y1—, alkynyl-Y1—, aryl-Y1—, heteroaryl-Y′—, —ORb, or —SRc, wherein Rb is a blocking moiety;each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil, or modified nucleobase;each instance of J is S, Se, or BH3;v is an integer of 1;OA is connected to a linking moiety connected to a solid support or a linking moiety connected to a nucleic acid;A is an acyl, aryl, alkyl, aralkyl, or silyl moiety; andG1, G2, G3, G4, and G5 are independently hydrogen, alkyl, aralkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heteroaryl, or aryl, or two of G1, G2, G3, G4, and G5 are G6 which are taken together to form a saturated, partially unsaturated or unsaturated carbocyclic or heteroatom-containing ring of up to about 20 ring atoms which is monocyclic or polycyclic, fused or unfused and wherein no more than four of G1, G2, G3, G4, and G5 are G6. 84. The method of claim 1 wherein the nucleic acid comprising a chiral X-phosphonate moiety contains from about 10 to about 100 nucleosides. 85. The method of claim 84 wherein the nucleic acid comprising a chiral X-phosphonate moiety contains about 15 to about 25, about 20 to about 30, or about 25 to about 35 nucleosides. 86. The method of claim 84 wherein each instance of X is independently an optionally substituted group selected from alkylthio, alkenylthio, alkynylthio, and —S−Z+. 87. The method of claim 3 wherein n is an integer of 10 to about 100. 88. The method of claim 87 wherein n is an integer of about 15 to about 25, about 20 to about 30, or about 25 to about 35. 89. The method of claim 87 wherein each instance of X is independently an optionally substituted group selected from alkylthio, alkenylthio, alkynylthio, and —S−Z+. 90. The method of claim 89 wherein each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or 5-methylcytosine. 91. The method of claim 6 wherein each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or 5-methylcytosine. 92. The method of claim 8 wherein: W1 is NG5 and W2 is O;at least one of G1 and G2 is not hydrogen; andG5 and G3 or G5 and 4 are taken together to form a saturated, partially unsaturated or unsaturated heteroatom-containing ring of up to about 20 ring atoms which is monocyclic or polycyclic, fused or unfused. 93. The method of claim 9 wherein J is O and D is H. 94. The method of claim 93 wherein each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or 5-methylcytosine. 95. The method of claim 9 wherein J is S and D is a moiety of Formula A, and wherein W1 is NG5 and W2 is O. 96. The method of claim 95 wherein each instance of Ba is independently a blocked or unblocked adenine, cytosine, guanine, thymine, uracil or 5-methylcytosine. 97. The method of claim 96 wherein: at least one of G1 and G2 is not hydrogen; andG5 and G3 or G5 and 4 are taken together to form a saturated, partially unsaturated or unsaturated heteroatom-containing ring of up to about 20 ring atoms which is monocyclic or polycyclic, fused or unfused.
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.